-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Maintains Outperform on Chemours, Lowers Price Target to $14

Benzinga·05/08/2025 18:19:05
Listen to the news
RBC Capital analyst Arun Viswanathan maintains Chemours (NYSE:CC) with a Outperform and lowers the price target from $17 to $14.